Get I-Mab alerts:Valuation and EarningsThis table compares I-Mab and its rivals revenue, earnings per share and valuation. Gross Revenue Net Income Price/Earnings Ratio I-Mab $3.89 million -$46.27 million -4.94 I-Mab Competitors $691.69 million $21.52 million -12.68Analyst RatingsI-Mab’s rivals have higher revenue and earnings than I-Mab. This is a summary of current ratings and target prices for I-Mab and its rivals, as reported by MarketBeat. I-Mab Company Profile(Get Free Report)I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics.